We don't have enough good studies to say if certain gene changes affect how your body processes omega-3 fats like EPA and DHA — the results so far are all over the place.

What we've found so far is that there isn’t enough strong evidence to say whether ELOVL gene variants like rs953413 and rs2236212 affect EPA and DHA levels in the blood [1]. Our analysis of the available research shows that while 20 studies or assertions support the idea that these gene variants could play a role, the actual results from these studies are inconsistent and don’t provide a clear pattern [1]. We’ve reviewed the data carefully, and what we see is a lack of reliable, high-quality studies that directly link these specific genetic changes to measurable changes in omega-3 fat levels. Even though there are 20 supporting assertions, they don’t point to a consistent effect—some suggest a link, others don’t, and many conflict with each other [1]. This means we can’t draw any firm conclusions about how these genes influence EPA and DHA in the bloodstream. Our current analysis shows the evidence is too scattered to support a clear connection. We’re not seeing strong, repeatable findings that would allow us to say these variants make a meaningful difference in how the body handles omega-3s [1]. Because of this, we can’t determine if people with these gene variants need more or less dietary EPA and DHA. The bottom line: based on what we’ve reviewed so far, we don’t have enough reliable data to say whether these ELOVL gene changes impact omega-3 levels. More consistent, well-designed studies are needed before we can understand any possible link. Practical takeaway: Don’t make changes to your diet or supplements based on these gene variants—there’s not enough solid evidence to guide that decision.